Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Briel

Showing results (11-20 of 288) with videos related to

Pageof 29
Sort By:
Deutsches Arzteblatt International|September 7, 2016
In ReplyHannah Ewald, Viktoria Gloy, Matthias Briel
JAMA Network Open|June 2, 2021
Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost ManagementStuart McLennan, Alexandra Griessbach, Matthias Briel, et al.
Journal of Clinical Epidemiology|August 2, 2023
Guidance needed: where should randomized studies which do not assess a health outcome be registered?Benjamin Speich, Sara Schroter, Matthias Briel
Medizinische Monatsschrift Fur Pharmazeuten|January 7, 2016
[Instructions for aggregated evidence: Systematic reviews and meta-analyses (part 1)]Birgit Schindler, Matthias Briel, Judith Günther
Medizinische Monatsschrift Fur Pharmazeuten|September 15, 2015
[Why bother with regression models?]Birgit Schindler, Matthias Briel, Judith Günther
Medizinische Monatsschrift Fur Pharmazeuten|September 15, 2015
[About the certainty of study results. What p-value and confidence intervalls tell us on it]Judith Günther, Matthias Briel, Katja Suter
Medizinische Monatsschrift Fur Pharmazeuten|September 10, 2015
[Four numbers and basic knowledge of mathematics]Katja Suter, Matthias Briel, Judith Günther
Swiss Medical Weekly|March 13, 2012
Meta-analyses: what they can and cannot doAlain J Nordmann, Benjamin Kasenda, Matthias Briel
Journal of Clinical Epidemiology|April 17, 2020
The fragility of trial results involves more than statistical significance aloneStephen D Walter, Lehana Thabane, Matthias Briel
JAMA|September 14, 2016
Colchicine and Prevention of Cardiovascular EventsLars G Hemkens, Hannah Ewald, Matthias Briel
Pageof 29

Showing results (11-20 of 288) with videos related to

Sort By:
Pageof 29
Deutsches Arzteblatt International|September 7, 2016
In ReplyHannah Ewald, Viktoria Gloy, Matthias Briel
JAMA Network Open|June 2, 2021
Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost ManagementStuart McLennan, Alexandra Griessbach, Matthias Briel, et al.
Journal of Clinical Epidemiology|August 2, 2023
Guidance needed: where should randomized studies which do not assess a health outcome be registered?Benjamin Speich, Sara Schroter, Matthias Briel
Medizinische Monatsschrift Fur Pharmazeuten|January 7, 2016
[Instructions for aggregated evidence: Systematic reviews and meta-analyses (part 1)]Birgit Schindler, Matthias Briel, Judith Günther
Medizinische Monatsschrift Fur Pharmazeuten|September 15, 2015
[Why bother with regression models?]Birgit Schindler, Matthias Briel, Judith Günther
Medizinische Monatsschrift Fur Pharmazeuten|September 15, 2015
[About the certainty of study results. What p-value and confidence intervalls tell us on it]Judith Günther, Matthias Briel, Katja Suter
Medizinische Monatsschrift Fur Pharmazeuten|September 10, 2015
[Four numbers and basic knowledge of mathematics]Katja Suter, Matthias Briel, Judith Günther
Swiss Medical Weekly|March 13, 2012
Meta-analyses: what they can and cannot doAlain J Nordmann, Benjamin Kasenda, Matthias Briel
Journal of Clinical Epidemiology|April 17, 2020
The fragility of trial results involves more than statistical significance aloneStephen D Walter, Lehana Thabane, Matthias Briel
JAMA|September 14, 2016
Colchicine and Prevention of Cardiovascular EventsLars G Hemkens, Hannah Ewald, Matthias Briel
Pageof 29